History

2023

May New approval for ‘Closartan’, a combination drug for high blood pressure with a low-dose diuretic (Korea)
Recommendation by IDMC to continue the global phase 2 clinical trial of Hanmi Pharmaceutical's NASH treatment
Apr Introduction of 7 research projects, the largest number of cases in Korea, at the AACR
Publishment of Rosuzet sub-study ‘Racing’ results in the 'American Heart Association'
Launch of SGLT2i-type dapagliflozin-based diabetes treatment ‘Dapalon Family’
Achievement of KRW 361.7 billion in sales and KRW 60.5 billion in operating profit, a 48% increase in the first quarter
Mar Participation in ‘2023 Bio Europe Spring Conference’
13th general meeting of shareholders, appointment of Jae-Hyun Park as the new CEO of the Manufacturing Division
Fed Achievement of highest record in sales, KRW 1,331.7 billion
1^st rank for outpatient prescriptions for 5 consecutive years (Korea, based on UBIST)
Jan Publishment of the results of the sub-analysis of the Rosuzet study ‘Racing’ in the ‘European Heart Journal’
Presentation of the New Year Management Slogan, ‘New 50 years, Global Hanmi!’

2022

Dec Acquisition of ‘AAA’ by the Fair Trade Commission for consecutive 4 years (first time in Korea)
Launch of Korea’s first sustained-release PPI gastritis treatment ‘Esomezoldial 10mg’
Inclusion of 'Rolvedon' by US NCCN in treatment guidelines for 32 cancer centers in the US
Awarded 1^st place in 2022 Korea Sustainability Competition, pharmaceutical industry sector, for 3 consecutive years
Awarded the Minister Prize for Corporate Innovation by the Ministry of Trade, Industry and Energy
Awarded the Minister Prize for Information Protection by the Ministry of Science and ICT
Nov Hanmi Science Merge with its affiliate Hanmi Healthcare
Excellent Presentation Award for ‘hypertensive low-dose triple fixed-dose combination’ from the Korean Society of Hypertension
Selection of immune anti-cancer drug under development HM16390, as a national new drug development task
Confirmation of complete remission for 3 doses of ‘Tuspetinib’
Oct Awarded Best Human Resource Development Organization for 2 consecutive times
Development of a ‘low dose-high blood pressure, triple fixed-dose combination’ for the first time in Korea
Designation of LAPSTriple Agonist INN as 'efocipegtrutide' by the WHO
Launch of neutropenia treatment ‘Rolvedon’ in the US
Sep US FDA Approval for the new bio-drug ‘Rolontis’
Aug Publishment of the Rosuzet study ‘Raicing’ in the July issue of ‘LANCET’, the world-leading medical journal
Launch of ‘Closartan’, a combination of ‘Losartan + Chlorthalidone’ for hypertension treatment
Jul Pyeongtaek Bio Plant obtains ‘Best’ grade in PSM(Process Safety Management) evaluation
Jun Achievement of ‘20 cases’, the highest number of orphan drug designations, in Korea
May Launch of Amosartan in the Chinese market under the brand name ‘Meiyaping’
Fast-track designation from the FDA for AML innovative new drug MKI(HM43239)
Apr Announcement of a next-generation anti-cancer drug at the AACR
Mar Launch of the world’s first ‘Esomeprazole + Magnesium Hydroxide’ FDC ‘Esomezol Plus’
Launch of osteoarthritis treatment injection ‘Hyaluma’ in the US market
Fed Awarded the Korea New Drug Development Grand Prize for the new bio-drug ‘Rolontis’
Jan Strategic investment of KRW 24 billion in Spectrum
Transfer of Chinese sales rights for innovative new ophthalmology drug ‘Luminate’ to Affamed
1^st rank for outpatient prescriptions for 4 consecutive years (Korea, based on UBIST)

2021

Dec Hanmi Received the Presidential Award at the ‘Korea Brand Award’
Poziotinib applied for FDA NDA approval
Nov Hanmi-Aptose, signed FLT3 Inhibitor License Agreement
Hanmi Ranked No. 1 in the Sustainability Management Index for 2 consecutive years
First biologic drug 'Rolontis' launches in Korea
Oct Hanmi founder Memorial Hall opened in the Seoul headquarters
MD Anderson Cancer Center announces “the potential of poziotinib therapy”
Lancet, a global medical journal, regards cardiovascular safety of ‘efpeglenatide’
Sep Clinical results of Poziotinib, listed in Journal of Clinical Oncology
Pentambody applied drug, clinical results first published in China
Rosuzet' launches 2.5mg low-dose product
Aug 1st rank for outpatient prescriptions in the first half for 4 consecutive years
Jul Hanmi-Lego ChemBio jointly develop dual antibody ADC anticancer drug
NIH visits Hanmi Fine Chemicals on-site verification of mRNA competency
Jun Founder of Hanmi, 'Lim Seong-ki Foundation' launched
Joint research on innovative new drug targeting lung cancer with Dankook University
May President Woo, received the Gold Tower medal of Industrial Merit on the Day of Invention
Hanmi-Genexin, Covid 19 Vaccine Production Contract
US FDA additionally designates LAPSTriple Agonist as an orphan drug
Apr AmosartanQ enters Russian Market
US FDA designates LAPSGLP-2 Analog as a Fast Track
Hanmi received a commendation from the Fair Trade Commissioner
Mar Opened Daycare Center for children of employees
New biologic drug Rolontis, first approval in Korea
US FDA designates Poziotinib as a Fast Track
Rosuzet enters Mexico Market
Feb NASH Innovative Drug, awarded Korea New Drug Development Technology
Rosuzet achieved No. 1 in sales of prescription drugs in Korea
Launched the world's first 4 drug complex 'Amosartan XQ'
Jan 1st rank for outpatient prescriptions for 3 consecutive years
FDA approves Phase 2 clinical trial for two innovative drugs of Hanmi
Launched the world's first Esomeprazole double delayed release 'Esomezoldial'

2020

Dec Spectrum FDA pre-meeting succeeded, expected BLA application of'Poziotinib'
Hanmi presented the results of AML treatment clinical trials HM43239 at ASH
Athenex presented results of Oraxol Phase 3 clinical trials
Nov Hanmi-GC, aggreement on developing innovative new drugs in 'rare diseases'
MFDS approved 'Amosartan XQ', world first 4-combination durg
Oct Hanmi awarded National Assembly Women and Family Chairperson Award
JVM automatic dispensing machine 'NSP' launched in Norway
Sep Hanmi and MSD cooperation agreement on clinical trials and supply
US FDA designates “Oraxol” for priority review
Aug Hanmi presented the results of ^LAPS Triple Agonist clinical trial at EASL
Inauguration of Hanmi Pharmaceutical Group Chairman Song Young-sook
Hanmi and MSD License Agreement of ^LAPS GLP/Glucagon(Efinopegdutide) to develop NASH Treatment
Chairman Lim Seong-ki, founder of Hanmi Pharmaceutical Group, passed away
Jul Announced 2020 2Q earnings 243.4 billion won in sales, 19.8% R&Dinvestment against sales
Spectrum presents clinical trial results of Poziotinib Phase 2
^LAPS Triple Agonist receives designation for US FDA Fast Track
Jun ^LAPSGlucagon Analog receives FDA RPD designation
^LAPSGLP-2 Analog receives FDA RPD designation
Spectrum presents clinical trial results of Rolontis at AACR
Gugu' released in Japan as a BPH treatment
Announced 6 new clinical trial results at ADA
Released low-dose Amodipine(2.5mg)
Spectrum presents Phase 2 clinical trial results of Oraxol
May Hanmihealthcare donated 156,000 'Wanjun' soymilk
Applies Rolontis BLA to the KFDA
Apr Launched 'LIVE Symposium 2020'
Announced 2020 1Q earnings 288.2 billion won in sales, 19% R&D investment against sales
Hanmi Pharmaceutical set up an audit committee
Mar ^LAPSTriple Agonist receives FDA RPD designation for PSC and PBC
Feb Announced 2019 earnings 1.16 trillion won in sales, 18.8% R&D investment against sales
JVM Packaging System, Launched in Canadian Walmart
Announced 2019 earnings 110.1 billion won, increased 6.3 percent on-year
Hanmi announces the largest number of blockbuster products in 2019.
Signed a partnership with GC to develop Rare Disease new drugs
Jan Announced achieving 'Top 1' market share of hypertension medication in Korea
A Joint agreement with STANDIME on the Development for new drugs based on AI
Hanmi unveiled new R&D strategy at 38th JP Morgan Healthcare Conference
Certified International Standard for business continuity Management System (ISO22301)

2019

Dec Maintained CP-rated 'AA' for 6 years by the Fair Trade Commission
39th blood donation, a total of 8,218 participanted
Hanmi women's Association Hold 11th Charity flea market
Hanmi Wins Prime Minister's Award for 'Korea's Loved Companies'
Announced 2 new blood cancer drug at ASH
Patent court ruled nullifying drug-food pirates registration of 'palpal'
Hanmi Announced collaboration to develop FLX475 with RAPT
The 18th Hanmi Cham Prize for the Yonsei Missionary center and the Muryang
Nov PENTAMBODY Phase 1 clinical trial started
Hanmi Science, North Gyeongsang Province-POSTECH-Pohand signed MOU
Patent court ruled nullifying pirate trademark registration of 'palpal'
Oct Announced 2019 3Q earnings 265.7 billion won in sales, 20% R&D investment against sales
Spectrum, reapply Rolontis BLA to the FDA
The Korean doctor Association awarded Hanmi with a merit prize
Spectrum listed a clinical result of Poziotinib Posotinip study in the Kenssel medical journal
JVM, extension of pouch-roll production plant
Certified best institution for Human Resource Development (HRD) from government
Sep Atenex, Releases clinical result of Oraxol in ESMO
Hanmi presents clinical trial results of Four clinical outcomes at EASD
Amosartan, 11th clinical outcomes listed in the SCI-class international journal
Signed a partnership with Phanes to develop dual and multiple antibodies
Amosartan Plus-Q, first entered in Latin America market
GMP inspectors from 10 Southeast Asian countries visited Paltan Smart Plant
Spectrum, disclosed Poziotinib
Hanmi selected as an Innovative pharmaceutical company ranking No. 1 in Korea and No. 12 in Asia
Aug Atenex Announce key clinical results of phase 3 clinical trial
Jul Announced 2019 2Q earnings 270.4 billion won in sales, 17% R&D investment against sales
Spectrum added poziotinib cohort three study
Jun CEO Kwon Se Chang awared 'KASBP Appreciation Award' at KASBP spring symposium
Confirms global competitiveness innovative drugs for NASH, rare diseases and targeted anti-cancer
Spectrum and Atenex Announce results of new drugs
Spectrum presents clinical trial results of Belvarafenib at AACR
May Phase 3 results of “Rovelito” were published in the international journal
Spectrum "'poziotinib’ global phase 2 cohort two study patient collection completed"
Hanmi receives FDA orphan drug designation fin treatment of short bowel syndrome
Apr JVM Packaging System, Launched in the Russian market
Genetech presents 4 results of clinical trial at AACR
Mar Co-promotion agreement of ‘Diquas’ with Santen
Received Seoul Metropolitan Government's Best Practices for Public Taxpayers
Rovelito Released clinical results of Phase 4 in the international journal
Feb Hanmi Pharmaceutical-MPO, 7th concert was succesfully ended
Hanmi Pharmaceutical set up an audit committee
Jan Announced 2018 earnings 1.16 trillion won in sales, 19% R&D investment against sales
Certified International Standard for Information Protection Management System (ISO27001)
Hanmi unveiled new R&D strategy at JP Morgan Healthcare Conference
Oraxol Global 3-phase patient collection completed
Spectrum "'poziotinib’ global phase 2 cohort one study patient collection completed"

2015

DecJVM launches new pharmaceutical packaging machine that can speed up the automatic dispensing procedure and save wrapping paper
LAPSCOVERY applied new bio drug Rolontis submitted for US FDA approval
NovEurope’s No.1 Pharmacy chain adopts JVM ‘s automatic pharmaceutical packaging machine
Hanmi conducts full-scale anti-smoking campaign at all its workplaces
OctHanmi presents clinical trial results of the treatments applied with LAPSCOVERY technology at EASD
Athenex gets FDA nod for testing oral breast cancer treatment, Eribulin
Hanmi receives FDA orphan drug designation for HM43239 in treatment of AML
SepSpectrum unveils the latest interim results of the phase 2 clinical trial on ‘poziotinib’ at WCLC
AugMonterizine Capsule phase 3 clinical test results featured in the Journal of Clinical Therapeutics
JulReleases phase 3 clinical result of Rolontis in an oral presentation at the MASCC
Slated to market and sell Hugel’s Gugu-fill(Hyaluronic Acid Filler)
Jun.Presents three next-generation anti-cancer drugs at ASCO
Releases clinical results of Amosartan/Rovelito at ESH
Launches Monterizine Chewable Tab for children
MayWins FDA nod for arthritis treatment ‘Hyalrheuma’
Sanofi begins phase 3 trials of Hanmi’s diabetes drug candidate ‘efpeglenatide’
Apr Janssen starts phase 2 study on HM12525A, a biologic drug for the treatment of diabetes and obesity developed by Hanmi
Unveils three new anti-cancer drug candidates at AACR
Spectrum presents clinical trial results of poziotinib at AACR
Wins FDA approval of ^LAPSTriple Agonist phase 1 clinical trial
Oraxol gets orphan drug designation for angiosarcoma
JVM, an affliliate of Hanmi awarded for excellence in corporate disclosure
Spectrum publishes the trial results for poziotinib, a non-small-cell lung cancer treatment on Nature Medicine
Mar Hanmi Tams 0.4mg phase 3 clinical test results featured in the Journal of Clinical Therapeutics
Selected the short track speed skating gold medalist Kim Alang as its new model for Tenten, a chewable nutritional supplement
Feb^LAPSGlucagon Analog receives FDA Breakthrough Therapy Designation in congenital hyperinsulinemia
Spectrum presents ‘Rolontis’ met the Primary Endpoint in the Phase 3 ADVANCE study… sets to file BLA within 4Q
Sanofi sets to start two phase 3 clinical trials of efpeglenatide in 2018
Received industry first ‘BPW Gold Award’ for promoting gender equality
JanPromotes innovative drugs for NASH, rare diseases and targeted anti-cancer at JP Morgan event
Reports 916.6 billion won in revenue in 2017, operating profit soars 212.3%

2015

DecHosts employee-driven charity events to make kimchi to support underprivileged
NovAdopts industry-first ISO 37001 to prevent illegal rebates and organizational corruption
Sanofi starts phase 3 clinical trials on Hanmi’s diabetes treatment ‘efeglenatide’
‘Amosartan Q’ phase 3 clinical test results featured in the Journal of Clinical Therapeutics
JVM receives 2017 Korea Technology Awards for its automated drug management system ‘INTIpharm’
OctPhase 3 results of ‘Amosartan Plus’ were published in the Journal of Clinical Therapeutics
Spectrum highlights poziotinib in at WCLC
Releases hypertension-hyperlidipemia three-compound complex Amosartan Q(amlodipine +losartan+rosuvastatin)
SepPresents the clinical trial results of NASH, rare diseases and targeted anti-cancer drug at EASD
Released 3-compound hypertension drug ‘Amosartan Plus (losartan/amlodipine/chlortalidon)’
AugPhase 3 results of ‘Gugutams’ were published in the Journal of Sexual Medicine
JulyHanmi launched the first osteoporosis therapy in the world which combines SERM with Vitamin D
Hanmi received approval of Amosartan Q, a hypertension-hyperlipidemia three-compound complex
Hanmi’s Esomezol listed in U.S. drug encyclopedia
Hanmi launched ‘Monterizine’, a combination drug for patients with both asthma and allergic rhinitis
JunHanmi presented its 2 candidate substance of biologic applied with ‘LAPSCOVERY’ at ADA
Hanmi presented the clinical trial results of hypertension three-compound complex at EHS
Hanmi won approval for Amosartan Plus, a 3 in 1 combination drug for hypertension
April ‘RaboneD’, a first combination drug of Raloxifene HCI and Cholecalciferol approved for sale in Korea
Hanmi launched ‘Besigum’, a treatment for overactive bladder syndrome treatment
May Hanmi received approval of a 1st-phase clinical test of the combination therapy of RAF target anti-cancer drug HM95573
'Monterizine', a first combination drug for asthma-rhinitis approved for sale in Korea
Phase III trial results of 'Gugutams' presented at 2017 AUA
Jan Hanmi-MSD, signed an agreement to export “Rosuzet” to export to 23 countries
Hanmi unveiled new R&D strategy at JP Morgan Healthcare Conference

2015

DecPreclinical trial results of “HM95573 (pan-RAF inhibitor)” were presented at Europe Cancer Symposium
Hanmi and Ajou University entered into a new anticancer drug development partnership for the development of a novel stem cell therapy
Hanmi launched Korea’s first urological combination drug for prostatic hypertrophy and erectile dysfunction “Gugutams”
NovPhase 3 results of “Rovelito” were published in the international science journal
SepPhase 3 clinical trial results of tamsulosin-tadalafil combined treatment “Gugutams” won the best subject award at the International Society for Sexual Medicine (ISSM)
Hanmi signed an exclusive license agreement with Genentech for a Novel Oral RAF inhibitor
AugPhase 3 results of “Rosuzet” were published in the international science journal
JulHanmi Pharmaceutical Group to establish venture capital firm ‘Hanmi Ventures’
Hanmi presented the research results of long acting diabetes-obesity medicines at 2016 ADA
Hanmi Science acquires medication management automation company JVM
JunHanmi presented the clinical trial results of two targeted anti-ancer drugs at 2016 ASCO
AprHanmi wins presidential citation for playing model role in promoting compliance program
Hanmi Science purchases land in Yantai Economic & Technological Development Zone in China
MarSpectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor
Hanmi launches Prostatic Hyperplasia medication ‘Hanmi Tams 0.4mg’
Hanmi launches antiviral medication ‘Hanmi Flu’
FebHanmis’ sales reach record high of KRW 1.3175 trillion
Hanmi attends JP Morgan Healthcare Conference, presenting new R&D projects
JanHanmi founder and chairman, Lim Sung-ki to give away shares worth KRW 110 bil. to employees

2015

Dec Hanmi launches oral wound rinse ‘MuGard’ for cancer patients
3rd-generation EGFR TKI, HM61713(Olmutinib), receives FDA Breakthrough Therapy Designation in lung cancer
Spectrum Announces Agreement with FDA on the Special Protocol Assessment(SPA) for the Registrational Trial of eflapegrastim, a Novel, Long Acting G-CSF in Patients with Breast Cancer
Nov Hanmi and Sanofi Announce License Agreement To Develop Portfolio of Long-Acting Diabetes Treatments
Hanmi and ZAI Lab execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China
Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol to FDA as Part of an Investigational New Drug(IND) Application for Poziotinib
Hanmi launches new dual-action hyperlipidemia drug 'Rosuzet'
Hanmi Signs an Exclusive License Agreement with Janssen Pharmaceuticals, Inc. to Develop a Novel Biologic for Treatment of Diabetes and Obesity
OctHanmi set new record in sales in Q3
Hanmi Enters Agreement with Serenus Bio to Bring Combination Therapy to Fight off Hypertension in Africa
SepHanmi presented the results of Efeglenatide's Phase IIb clinical trial at 2015 EASD
AugHanmi Enters Research Collaboration for a Next Generation Biologic Drug with a Bio-Venture
JunHanmi to Present 3rd-generation EGFR TKI, HM61713 at 2015 ASCO
Hanmi to Present its New Diabetes Drugs Including Quantum Project at 2015 ADA Scientific Sessions
AprHanmi to Build “Global Smart Facility” for Export of Finished Products
MarLicensed out ‘Poziotinib’ (targeted anticancer agent) to Spectrum Pharma in US
Beginning US Phase Ⅲ clinical trial for its osteoarthritis medicine Hyalrheuma
Licensed out immunological therapy ‘HM71224’ to Eli lilly (Deal size : 780 bil won)
Started phase 2 clinical trial of new antibody target lung cancer drug, HM61713
Presented a new long-acting human growth hormone drug (^LAPSrhGH) at the endocrine society conference
FebInitiated phase I clinical trial of first in class weekly insulin in US
Targeted anti-cancer agents Poziotinib, goes on phase 2 to expand indications for Breast cancer
JanCP Grade impoved from BBB to A
Participated in JP Morgan healthcare conference
$20 million strategic investment with Allegro Ophthalmics(ophthalmic Bioventure)
Initiated phase I clinical trial of first in class weekly insulin in US
35th Blood Drive...a total of 4,883 people participated
Co promotion agreement of ‘Godex’ with Celltrion

2014

NovHanmi new RFID reader, grand prize for national excellence patent award
Phase 1 clinical trial of HM95573,a next-generation targeted therapy for melanoma treatment
OctBeijing Hanmi, received 'Presidential Prize' at 2014 Korea well-respected corporate awards
Received 'Minister Prize of Health and Welfare' at Sharing Korea awards
SepDiabetes-obesity biologics, presented at EASD
AugLicense agreement with Luye pharma group for targeted anti-cancer dug 'Poziotinib' in China
Diabetes biologic, '^LAPS efpeglenatide', completed patient recruitment in phase IIb clinical trial
JulContract with Actavis for exporting a hyaluronic acid injection
Hanmi opened the official blog 'Saranghanmida'
Hanmi-Novartis, diabetes treatment 'Galvus' co-promotion
JunTriaxone, obtained market authorization in 4 EU countries
LAPSInsulin, weekly diabetes drug, presented at ADA
Rheumatoid arthritis drug, HM71224, presented at EULAR
The 8th Hanmi mid-small hospital award, Seungwon Hong, Director of Daejeon Christian General Hospital
Plant in Pyeongtaek awarded for joining PIC/S by Korea Food & Drug Administration
May Diabetes-obesity new drug (^LAPS-GLP-1/GCG) enters into global phase 1
Apr Probiotics for kids in Beijing Hanmi, 'Mamiai' is registered as China Famous Trade Mark
Decided to build an extension of BioPlant in Pyeongtaek
Received 'fair trade corporation' award by Fair Trade Commission
Launched Fluterol, DPI type asthma treatment drug
Mar 4th shareholders meeting of Hanmi Pharmaceuticals / 41st shareholders meeting of Hanmi Science
License agreement with Access Pharmaceuticals for Korean commercialization of 'Mugard'
Feb Hanmi-MSD, mutual co-promotion agreement for the sales of 12 products
Succeeded in seasoned equity offering (1 million shares)
Jan Hit 100 billion won in research and development as the first listed pharmaceutical company
Only one in the pharmaceutical industry to receive CP certificate(BBB grade)

2014

DecHIMD for the treatment of gastroesophageal reflux disease, Esomezol, launched in the United States
Hanmi- Sanofi launched Robelito, the first ARB-Statin combination drug in Korea
NovHanmi launched Naxozol, a NSAIDs-PPI combination drug
OctTargeted anti-cancer drug candidate, HM61713, presented recent clinical study during WCLC
LAPS-Exendin4 progresses to Multi-National Phase IIb Clinical Studies
SepHanmi awarded best biotechnology corporation prize by Korean Ministry of Trade, Industry and Energy in recognition of LAPS-GCSF development
RFID history management solution, KEIDAS, achieves 'GS1 EPCglobal' certification
AugStudy on Pidogul, anti-thrombotic drug, published in AJCD/Clinical Therapeutics
Anti-reflux esophagitis, Esomezol, receives marketing authorization in the US through 505(b)2 procedure
JulTargeted anti-cancer drug candidate, HM61713, enters multiracial Phase I study
License agreement with Wakamoto for Korean commercialization of MaQaid
Export Hanmi IMD (Esomezol, Amosartan, Pidogul), seven countries in SE Asia through DKSH
Hepatitis C drug(LAPS-IFNα), Phase II underway in Latin America
Chinese Hospital Pharmacists Association visits Hanmi headquarters and R&D center
Hanmi melanoma treatment candidate, selected to receive government support
Hanmi antibiotic powder injection, achieves the first EU GMP acquisition in the nation
Hanmi rheumatoid arthritis drug, Phase I on the European cruise
Jun The 7th Hanmi mid-small hospital award, Yutae Jeon, the CEO of Inbong Medical Association
Hanmi-Sanofi Korea’s first request for approval, ‘ARB-statin’ a complex new drug
Hanmi enters Phase 3 studies, natural new drug for abdominal obesity
May Hanmi receives the global ‘best RFID deployment’ award
‘Esomezol’ IMD of Nexium, apply for a first marketing authorization to the U.S. FDA
Apr Complex new drug ’Ibastin’ (hypertension + hyperlipidemia), manufacturing technique patent
‘Pidogul’ platelet aggregation, listed on international journals (Clinical Therapeutics)
Hanmi global biopharmaceuticals ‘LAPS-GCSF’, enters Phase II in the U.S.
Mar Pharmacy-only energy drink, ‘Premium Recipe’ released
Feb 12th annual essay prize award
Nasal aerosol rhinitis treatment, ‘Moteson Plus’ released
‘Amosartan’ licensed in the three states of CIS and Uzbek
1st Sound of Light sharing concert
Global cancer new drug KX2-391, domestic clinical plunge
Jan Online Pharm enters automatic prescription equipment market
'Fenocid' launched for the management of neutral fat

2014

Dec Formulation patent for stabilization of targeted anticancer drug granted
The 5th Hanmi Proud MD award, Dr. Muyeol Park (Goramdola hospital)
Hanmi and Kainos collaborate on new drug development
NovAppreciation plaque from the Korean Red Cross
Fixed-dose combination 'Irbestin' collaboration with Sanofi
Oct Medicine donation for North Korean flood victims
US patent granted for next generation antimycotics formulation
Sep Medicine donation to Pyongyang Mankyungdae Univ. Hospital
Aug LAPS-Exendin for type 2 diabetes, selected as a government supported project
Launched low-dose erectile-dysfunction medication
July Launches PalPal Chew Tab. 50mg
July Selected as a Pharmaceutical Company of Innovation, by Ministry of Welfare
AprIn-licensing deal with SK Biopharmaceuticals for development and commercialization of Diazepam Nasal Spray
Beijing Hanmi, accredited as 'R&D Center' by Beijing Government
Received the CE mark for Hyalrheuma from UK SGS
MarHanmi-GSK, Collaboration agreement for FDC development
Launched Koennasal spray (Hyalu acid+Dexpantenol)
Hanmi Holdings changed name from Hanmi Holdings to Hanmi Science
New anti-obesity, diabetes drug (HM47000), chosen as new drug development program by government
FebThe 11th Hanmi literature awards
License agreement for anti obesity botanical drug (ALS-L1023)
'Amosartan' published in international academic journals (BMC, AJCD, Clinical Therapeutics)
JanLAPS-GCSF, Collaboration with Spectrum (US)
Supply agreement for 13 OTC drugs with MEIC(Mongolia)
LAPS-GCSF, Collaboration with Spectrum (US)

2014

Dec Hanmi Pharmaceutical’s first shipment of ‘AMOSARTAN’ made to MSD
Hanmi’s ‘ORASCOVERY’ technology, licensed out to USA
Nov Orphan drug designation for LAPS-rhGH applied for
Amosartan clinical study is published on BMC Research Note
Oct Phase II study of long-acting human growth hormone in European territories
JunRetail pharmacists answer that Hanmi's sales reps are the kindest and the most impressive
May Hanmi expands its licensing agreement with Merck
Apr Hanmi signs a collaboration agreement with Kinex to develop and market a novel anti-cancer drug candidate, KX-01
Mar Esomezol receives IR52 Jang Young-Shil Award from KOITA
Hanmi's Amosartan ranked the second highest for detailing drugs
Feb Hanmi strengthens R&D with a new external collaboration unit
Hanmi's Clopidogrel, approved in European countries
Jan Hanmi`s Esomezol wins IR52 Jang Young-Shil Award
Filed letter with FDA for modified Esomeprazole Capsule
R&D reinforcement with a new external collaboration unit (eR&D)

2010

DecHanmi transfers entecavir synthetic methods to Hwail
Hanmi showcases RFID system in 'RFID/USN KOREA 2010'
Beijing Hanmi wins Korea-China Corporate Management Grand Prize
NovUK MHRA recommends approval of Pidogul
OctHanmi submits IND application for Irbesartan-Atorvastatin combo
SepHanmi receives IR52 Jang Young-Shil Award from KOITA
AugHanmi initiates the clinical trials of Amosartan in Europe
Hanmi ranks 1st in R&D investment among Korean pharmaceutical companies
Hanmi submits IMPD in Europe for phase I clinical trials of LAPS-Exendin
JulAmosartan, approved as the initial therapy among CCB+ARB hypertension combo drugs
Hanmi submits IMPD in Europe for phase I clinical trials of LAPS-Exendin
MayPhase I underway for Atorvastatin plus Aspirin fixed dose combination drug
JunHanmi wins the best drug research award from KDRA
AprLAPSCOVERY Platform Technology obtains US Patents
FebAmosartan ranked the highest for detailing drugs
IND Application for long-acting human growth hormone approved
JanKFDA Approves IND application of once monthly Exendin4 analog

2014

2009 Co-promotion agreement with Lundbeck for Ebixa®, a treatment for Alzheimer’s disease
Amosartan®, an antihypertensive combination drug of Amodipine and Losartan, launched
Co-promotion agreement with GSK in respiration-allergy area
2008 Hanmi-Crystal genomics strategic alliance
2007 2007 KGMP approval on Cephalosporin finished product manufacturing facility in Pyeongtaek
First launching of anti-obesity drug ‘Slimmer®’(sibutramine mesilate)
2006 Successfu development of mexibufen syrup, using alternative salt
Published clinical study for Amodipine®
2004 Patent of Amodipine, a new salt form of Amlodipine, granted
Successful development of Fedipine table, a 24hr controlled-release formulation of Nifedipine
2003 Registered as Hanmi Photographic Museum with government
Hanmi Pharm. marking its 30-year foundation day anniversary
Changes into Hanmi Pharmaceutical Co., Lt
Designation of Hanmi’s central research labs as ‘ICE GMP Technology Center’
2002 Establishment of Hanmi Foundation of Art & Culture
Completion of Hanmi GMP plant in Beijing
2001 Development of oral antifungal agent ‘Itra tablet’ for 2nd in the world
2000 Successful development of oral anticancer drug Paclitaxel

2014

1998 Making inroads into the European markets through acquisition of COS for the first time in Korea
Successful production of G-CSF through transformed black goat ‘Medi’
1997 Hanmi Pharm. broke 100 billion won barrier in sales
1994 Development of cyclosporin A for the 2nd time in the world
Ground-breaking ceremony of Beijing Hanmi Pharmaceutical Co., Ltd
Technology transfer to Novartis (domestic market)
Technology transfer to Novartis (foreign market)
1993 Completion of Hanmi Pharm.’s headquarters at Bangi dong
1989 Technical transfer to Swiss-based Roche; process patent of ceftriaxone
Completion of Hanmi Fine Chem.’s Shiwha plant under newly expanded construction
1988 Hanmi Pharm, as listed company in Korea’s stock market
1987 Development of third-generation ceftriaxone antibiotic as inject-able form
1986 Accreditation of KGMP standards on all drugs
1985 Synthesis cephalosporin antibiotics
1984 New construction of Paltan GMP plant located at Paltan-myeon, Hwaseong-si, Gyeonggi-do
1983 Making of company motto
Establishment of Hanmi Fine Chemical Co., an affiliated company of Hanmi Pharm
1978 Making of company’s spirit ‘Creation, Justice, and Deed’
1974 Composition of sales force
1973First launching of trimethoprim sulfamethoxazole powder
Change into Hanmi Pharmaceutical Ind. Co., Ltd
Establishment of Lim, Sung-ki Pharmaceutical Co., Ltd

Company

About Hanmi